Highlights :
Key Ratio H /
Income H /
Balance Sheet H /
Cash Flow H |
Details :
Income D /
Balance Sheet D /
Cash Flow D |

NASDAQ / Sector: Healthcare / Sub-Sector: Biotechnology / Stock Type: Distressed
# of Employee: 100 / Fiscal Year End: 2018-12-31 / Stock Type: —
USD / Exchange Rate: 1 at 2016-11-22 / Estimation: $Confidential /

/ $

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Competitors | QuarterReport

Competitors List | Key Matrix Details

AKCA |

Finance Highlights

Key Ratio Highlights | Key Ratio H | Income H | Balance H | Cash H | Income D | Balance D | Cash D | Top

ReportDate	PeriodType	ROE	FCFMargin	FCFPerShar	EquityPerS	ProfitMarg	Continuous	NetMargin	DebtEquity	CurrentRat
2017-12-25	Annual	-20.20%	-65.60%	-1.2	5.9	100.00%	-198.80%	-198.80%	2.014	.303
2018-12-25	Annual	-73.70%	-314.50%	-2.5	3.4	81.90%	-348.10%	-348.10%	3.126	.302

Key Ratio Trend

ReportDate	PeriodType	ROE	FCFMargin	FCFPerShar	EquityPerS	ProfitMarg	Continuous	NetMargin	DebtEquity	CurrentRat
Average	Annual	-264.85%	-379.42%	-109.62%	-42.71%	-18.10%	-75.10%	-75.10%	55.21%	-0.33%
2018-12-25	Annual	-264.85%	-379.42%	-109.62%	-42.71%	-18.10%	-75.10%	-75.10%	55.21%	-0.33%

Income Statement Highlights | Key Ratio H | Income H | Balance H | Cash H | Income D | Balance D | Cash D | Top

ReportDate	PeriodType	Revenue	Cost	InterestEx	Continuous	NetIncome	DilutedSha	ProfitMarg	Continuous	NetMargin
2017-12-25	Annual	55,209k	0.0	1,731k	-109,751k	-109,751k	30,262,768	100.00%	-198.80%	-198.80%
2018-12-25	Annual	64,867k	11,733k	0.0	-225,821k	-225,821k	81,365,801	81.90%	-348.10%	-348.10%

Income Statement Trend

ReportDate	PeriodType	Revenue	Cost	InterestEx	Continuous	NetIncome	DilutedSha	ProfitMarg	Continuous	NetMargin
Average	Annual	17.49%	0.00%	-100.00%	-105.76%	-105.76%	168.86%	-18.10%	-75.10%	-75.10%
2018-12-25	Annual	17.49%	0.00%	-100.00%	-105.76%	-105.76%	168.86%	-18.10%	-75.10%	-75.10%

Balance Sheet Highlights | Key Ratio H | Income H | Balance H | Cash H | Income D | Balance D | Cash D | Top

ReportDate	PeriodType	Equity	TotalAsset	TotalLiabi	CurrentAss	CurrentLia	NonCurrent	DebtEquity	CurrentRat
2017-12-25	Annual	179,633k	268,804k	89,171k	266,845k	80,853k	8,318k	2.014	.303
2018-12-25	Annual	276,724k	365,261k	88,537k	267,235k	80,661k	7,876k	3.126	.302

Balance Sheet Trend

ReportDate	PeriodType	Equity	TotalAsset	TotalLiabi	CurrentAss	CurrentLia	NonCurrent	DebtEquity	CurrentRat
Average	Annual	54.05%	35.88%	-0.71%	0.15%	-0.24%	-5.31%	55.21%	-0.33%
2018-12-25	Annual	54.05%	35.88%	-0.71%	0.15%	-0.24%	-5.31%	55.21%	-0.33%

Cash Flow Highlights | Key Ratio H | Income H | Balance H | Cash H | Income D | Balance D | Cash D | Top

ReportDate	PeriodType	OperatingC	CAPEX	FreeCashFl	Investment	FinancialF
2017-12-25	Annual	-36,190k	-9k	-36,199k	-202,608k	289,401k
2018-12-25	Annual	-202,888k	-1,119k	-204,007k	70,545k	162,831k

Cash Flow Trend

ReportDate	PeriodType	OperatingC	CAPEX	FreeCashFl	Investment	FinancialF
Average	Annual	-460.62%	-12,333.33%	-463.57%	134.82%	-43.74%
2018-12-25	Annual	-460.62%	-12,333.33%	-463.57%	134.82%	-43.74%

Finance Detail

Income Statement Details | Key Ratio H | Income H | Balance H | Cash H | Income D | Balance D | Cash D | Top

{##IncomeSheetDetail}

Balance Sheet Details | Key Ratio H | Income H | Balance H | Cash H | Income D | Balance D | Cash D | Top

{##BalanceSheetDetail}

Cash Flow Details | Key Ratio H | Income H | Balance H | Cash H | Income D | Balance D | Cash D | Top

{##CashFlowDetail}

AKCA